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Abbreviations & Acronyms 
AAD   Antiarrhythmic drug 
AF   Atrial fibrillation 
AT   Atrial tachycardia 
AV   Atrioventricular 
BP   Blanking period 
CA   Catheter ablation 
CB   Cryoballoon 
CBG2   Second-generation CB 
CHA2DS2-VASc  Congestive heart failure/left ventricular dysfunction, hypertension, age  
                                    ≥75 years, diabetes, stroke, vascular disease, age 65–74, female sex 
CS   Coronary sinus 
CT   Computed tomography 
ECG   Electrocardiogram  
EHRA   European Heart Rhythm Association 
HAS-BLED Hypertension, abnormal renal / liver function, history of stroke / bleeding,  
 labile INR, elderly, drugs or alcohol 
ICE   Intracardiac echocardiography 
LA   Left atrium 
MRI   Magnetic resonance imaging 
PNP   Phrenic nerve palsy 
PV   Pulmonary vein 
PVI   PV isolation 
RF   Radiofrequency 
SVC   Superior vena cava 
TIA   Transient ischemic attack 
TTI   Time to isolation 
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Introduction 
Atrial Fibrillation 
With a prevalence of approximately three percent of the general population, atrial fibrillation (AF) 
is the most common cardiac arrhythmia (3-5). In general, AF is a non-lethal supraventricular 
tachycardia diagnosed by ECG documentation (6). Chaotic electric activity of the atria 
generates an atrial heart rate of at least 300 beats per minute followed by an irregular response 
of the ventricles due to AV node modulation (6). And although often asymptomatic (7), typical 
symptoms may occur including palpitations, chest discomfort and dizziness, dyspnea or 
reduction in exercise capability leading to a decrease of life quality (3, 6). AF impairs atrial 
contractility and, according to the Virchow triad (blood stasis, endothelial dysfunction, 
hypercoagulability), facilitates thrombus formation and therefore increases the risk of stroke and 
other thromboembolic events in AF patients (8, 9). Furthermore, AF may cause cardiac 
dysfunction and can decrease pre-existing cardiovascular disease to severe heart failure, 
consequentially, leading to an increase in morbidity and mortality (6, 10). AF is a dynamic 
disease and in the majority of cases the arrhythmia develops from paroxysmal AF in the 
beginning to persistent and permanent AF over time (6, 10). Several possible mechanisms 
(pulmonary vein sleeves merging into the left atrium, triggered activity, reentry, focal drivers, 
rotors, atrial fibrosis and more) (11-15) have been described for the initiation, transition and 
maintenance of AF (16). Individual characteristics such as arterial hypertension, structural heart 
disease, age, obesity, genetic predisposition influence above pathophysiological mechanisms 
(17). Therefore, the management of AF is complex and requires an individual approach. In 
general, there are three therapeutic goals: (a) the prevention of thromboembolic complications 
using oral anticoagulation whose indication depends on a risk-benefit assessment. The 
CHA2DS2-VASc score (Congestive heart failure/left ventricular dysfunction, Hypertension, Age 
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≥75 years, Diabetes, Stroke, Vascular disease, Age 65–74, and Sex category female) can 
estimate the thromboembolic stroke risk and the HAS-BLED score can estimate the bleeding 
risk for each patient (3, 10, 18, 19). Furthermore, a rate control therapy (b) that slows down the 
ventricular rate in AF, or, a rhythm control therapy (c) that aims to restore or maintain sinus 
rhythmus through electrical cardioversion, the use of antiarrhythmic drugs (AAD) or catheter 
ablation (CA) are available to reduce AF symptoms (3, 6, 10). Rhythm control can be achieved 
with interventional catheter ablation and is reserved for symptomatic patients with paroxysmal or 
persistent AF (3). It targets the pulmonary veins as arrhythmogenic PV triggers have been found 
in more than 90% of patients with paroxysmal and persistent AF (11, 20). Therefore, electrical 
pulmonary vein isolation (PVI) is the major goal in the catheter treatment of AF (21, 22). Today, 
radiofrequency (RF) energy is the dominant energy source in use to perform PVI (10, 23) but 
the novel cryoablation technique using a cryoballoon for PVI has attracted worldwide interest 
due to favorable results that were non-inferior to RF ablation (24, 25). In addition, the 
cryoballoon technique convinces with a faster operator learning curve, a high reproducibility of 
the results across various centers, a short total procedure time, higher catheter stability through 
cryoadhesion to the tissue and others (10, 23, 25-28). Nevertheless, outcome data for the 
second-generation of the cryoballoon (CBG2) are still limited and the preferred technique for the 
initial ablation procedure when PVI is the procedural endpoint has not yet been determined. In 
this cumulative dissertation, the main focus lies on PVI using the CBG2. Two studies 
investigating the clinical outcome and safety after initial CBG2-PVI in patients with paroxysmal 
or persistent AF have been published. The following sections provide more detailed information 
about AF types, the management and mechanisms of AF and will then focus on catheter 
ablation strategies and present results of both prospective single center observational studies. 
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Types of Atrial Fibrillation 
AF often evolves from rare and short events to more frequent and longer episodes. Next to the 
first diagnosis of AF, four main AF types are distinguished due to the clinical presentation of the 
arrhythmia (6, 22). “Paroxysmal AF” is defined as spontaneous conversion into sinus rhythm or 
the use of medical or electrical cardioversion within seven days. “Persistent AF” considers AF 
episodes that last longer than 7 days. In “longstanding persistent AF” a decision for rhythm 
control has been made after at least one year AF duration. When AF is accepted by both patient 
and the treating physician and no rhythm control strategies are pursued, the condition is 
classified as “permanent AF”. All AF types are summarized in Table 1. 
Table 1: AF types, definition and indications for catheter ablation.  Based on the 2012 
Heart Rhythm Society, European Heart Rhythm Association and European Cardiac 
Arrhythmia Society expert consensus statement on catheter and surgical ablation of 
atrial fibrillation (22), and the 2016 ESC Guidelines for the management of atrial 
fibrillation (3) 
 
AF type Definition Indications for Catheter 
Ablation 
first diagnosed Any AF first documented by ECG recording 
irrespective of the duration or symptoms 
_ 
paroxysmal Recurrent AF that terminates spontaneously 
usually within 48 hours but may continue up 
to 7 days. Episodes of AF ≤ 7 days’ duration 
that are terminated with electrical or 
pharmacological cardioversion should be 
considered as paroxysmal 
Class I / Level A 
 CA is recommended* 
Class IIa / Level B 
 primary CA therapy with-
out prior AAD treatment 
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persistent Continuous AF that is sustained beyond 7 
days. 
Class IIa / Level B 
 CA is reasonable* 
longstanding 
persistent 
Continuous AF ≥ 12 months’ duration Class IIb / Level B 
 CA could be considered* 
permanent A decision has been made to not restore or 
maintain sinus rhythm 
_ 
Class indicates recommendation, level indicates evidence. AF, atrial fibrillation; CA, 
catheter ablation; *) valid for symptomatic AF patients who were refractory or intolerant 
to at least one class 1 or 3 antiarrhythmic drug 
Management of Atrial Fibrillation 
The management of AF is complex and requires an individual approach mainly depending on 
AF burden, AF type, symptom score (EHRA I-IV) and patient’s preference, underlying heart 
disease, LA diameter, age and other comorbidities (6). Next to a diversity of treatment 
modalities the personalized therapy needs continuous reevaluation as AF is a progressive 
disease and the clinical course changes over time (29). Main strategies for the management of 
AF are aiming at oral anticoagulation to prevent thromboembolic events and a rate control 
and/or rhythm control therapy to reduce AF symptoms (6). The indication for oral 
anticoagulation is based on the CHA2DS2-VASc score that predicts the thromboembolic stroke 
risk in percent per year in AF patients. The score adds up two points for age ≥75 years or a 
history of stroke/TIA, and one point for age 65–74 years, arterial hypertension, diabetes 
mellitus, congestive heart failure, vascular disease and female sex. Antithrombotic therapy is 
recommended for all patients with valvular AF and patients with non-valvular AF who have 1 
stroke risk factor. It is not recommended for patients with lone AF who are 64 years or younger 
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(including females) (3, 10, 18, 19). To achieve rate control, pharmacological therapy that slows 
down the ventricular rate in AF is necessary to reduce symptoms and prevent tachycardia-
induced heart failure (29). Furthermore, AV node ablation including pacemaker implantation 
(“ablate and pace”) is another possibility for a small group of patients, e.g. in permanent AF with 
tachyarrhythmia despite optimal medical treatment (3, 6, 10). The goal of rhythm control, 
however, is to restore or maintain sinus rhythm by electrical cardioversion, the use of 
antiarrhythmic drugs (AAD), and catheter ablation (CA), or, at times, AF surgery (3, 6, 10). 
Catheter Ablation ─ Based on Mechanisms of Atrial Fibrillation 
Indications for CA are reserved for symptomatic, usually drug-refractory paroxysmal and 
persistent AF patients (Table 1) (3, 22). The primary goal of CA therapy is to ablate either the 
trigger that induces AF and/or to modify the substrate that leads to the maintenance of AF (22). 
Therefore, the understanding of pathophysiological mechanisms that initiate, maintain and lead 
to AF progression is important. Haïssaguerre et al. first described that the pulmonary veins (PV) 
as the source of ectopic beats are responsible for the initiation of paroxysmal AF (11). Others, 
for example further non-PV trigger sites (e.g. coronary sinus, crista terminalis, SVC, left atrial 
appendage) (30-33) or conduction disturbances, such as focal drivers (12) have also been 
named for initiating AF. Nevertheless, PVI ─ with the goal to electrically isolate the PV from the 
left atrium ─ has prevailed and has become the cornerstone in the catheter treatment of 
paroxysmal AF. The mechanisms underlying persistent AF are more complex and less 
understood. Next to pulmonary vein foci, other mechanisms that form an arrhythmogenic 
substrate are responsible for transitioning and maintaining the arrhythmia and can thus be 
target of ablation therapy. Examples are atrial fibrosis that causes reentry (13, 15), autonomic 
sources, rotors and focal mechanisms (14). Figure 1 summarizes the variety of different 
anatomic and pathophysiological mechanisms of AF and illustrates the diversity of possible 
therapeutic interactions. 
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Figure 1: Mechanisms of Atrial Fibrillation  drawing focusing the left atrium from 
posterior. Based on and adapted from Europace (22), Circulation (34), Am J Cardiol 
(35), Tex Heart Inst J (36). 
 
Yellow: ganglionic plexi and axons including Ligament of Marshall (LOM); Blue: coronary 
sinus (enveloped by muscle fibers with connections to the atrium); Red circuits: large 
and small reentrant wavelets; Red stars: common locations of pulmonary veins (PV); 
Green: common origins of non-PV triggers. LSVP indicates left superior PV; LIPV, left 
inferior PV; RSPV, right superior PV; LSPV, left inferior PV; SVC, superior vena cava; 
IVC, inferior vena cava. 
Energy sources for atrial fibrillation ablation 
With radiofrequency- (RF) and cryothermal energy, two main energy sources are established to 
perform CA for PVI. RF energy is still the dominant energy form in use (10, 23) since the first RF 
ablation for AF in 1994 (37). The newer cryothermal energy was first approved for AF ablation 
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using an over-the-wire cryoballoon technique in 2005 and seems to offer certain advantages 
over RF energy: 
1) Sharply demarked tissue destruction without or minimal endothelial damage leading to a 
5.6-fold lower risk of thrombus formation (27) 
2) Minimal tissue contraction with healing after re-warming results in fewer major complications 
such as PV stenosis and esophageal injuries (26, 28) 
3) Broad, wide antral circumferential ablation lesion leading to a durable PVI (38) 
4) Real time PV-potential recordings during the application allows to determine the “time-to-PV-
isolation” (TTI), an unique intraprocedural predictor for durable PVI (39) 
5) Higher catheter stability through cryoadhesion of the CB to the target tissue whereas RF-
catheters are prone to be instable (“free floating”) during the application. This might result in 
a more continuous circumferential lesion and in less injuries of surrounding anatomic areas 
(28, 40).  
6) In cryoablation there is no risk of steam pops which can occur in RF ablation from 
overheating. These  are the main contributors for pericardial tamponades in RF ablation (41) 
7) Pain-free ablation that is well tolerated by the sedated patient (42-44) 
8) Continuous circumferential lesion sets through homogenous refrigerant distribution within 
the balloon compared to focal point-by-point lesions with RF and the possibility of a “single-
shot” PVI making the CB procedure less complex and less operator dependent resulting in a 
shorter overall procedure time (23, 26, 27) 
9) Similar overall complication rate with fewer major complications (26); asymptomatic phrenic 
nerve palsy with a recovery rate of 99% is the main cryospecific complication (26) 
10) Less re-do ablation procedures, electrical cardioversions and re-hospitalizations during 
follow-up in paroxysmal AF (45) 
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Considerable disadvantages of cryoballoon ablation in comparison to RF ablation are a higher 
radiation exposure due to PV angiographies (46), no supportive 3D-mapping system that allows 
a reconstruction of the left atrium for anatomic non-fluoroscopic guidance of the ablation or AF 
substrate characterization (no voltage mapping) (46), and a less flexible catheter application 
without the possibility of potential substrate modification (47). 
Catheter Ablation Strategies 
Regarding the mechanisms of AF, various ablation strategies have been developed. For 
paroxysmal AF, PVI is the goal in the catheter treatment (21, 48). PVI can be achieved using 
RF-energy by the conventional point-by-point RF-ablation, or cryoballoon based ablation which 
allows a single-shot PVI. Due to more complex mechanisms in persistent AF, several empirical 
strategies using RF energy have been investigated (e.g. PVI plus trigger based ablation, linear 
ablations, ablation targeting complex fractionated atrial electrograms, stepwise ablation 
approach, etc.). The results have shown limited success rates and multiple procedures were 
often necessary (49-59). Furthermore, the STAR AF II trial has recently demonstrated that PVI 
alone was non-inferior to strategies with additional substrate modification. The authors even 
mentioned that more extensive ablation may induce new arrhythmogenic substrate (60). Hence, 
the preferred strategy for the treatment of persistent AF is still unclear and it is reasonable to 
obtain PVI alone with either RF- or cryoenergy even in persistent AF in the initial ablation 
procedure. 
As a result, cryoballoon based ablation has attracted increasing worldwide interest. Particularly 
since 2012, as the technically improved second-generation cryoballoon (CBG2) was released 
and impressed with an increase in refrigerant flow and a broader freezing zone (complete distal 
hemisphere of the balloon) leading to a more potent ablation in an equally safe procedure as 
compared to its predecessor (61-63). However, data were limited to smaller single-center 
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cohorts and the preferred cryoablation protocol for optimal lesion generation has not yet been 
determined. In this cumulative dissertation, CBG2-PVI was performed in two large patient 
populations with either paroxysmal or persistent AF. The following section will give information 
about the objectives and general approach of the research, the cryoablation procedure protocol 
and main findings. 
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Scientific Questions and Objectives 
The main goals were 
 To assess baseline characteristics, procedural data and periprocedural adverse event 
rates after PVI using the CBG2 in patients with symptomatic paroxysmal or persistent AF 
 To investigate the clinical outcome 12 months (freedom from AF, atrial tachycardia, AF-
related symptoms) excluding a 3-month blanking period 
 To provide additional data and to evaluate, whether cryoablation is a safe and effective 
treatment option and thus can be a first choice ablation strategy for the initial ablation 
procedure 
 To investigate the role of both balloon sizes: the small 23-mm CB and the large 28-mm-
CB 
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Own Contribution: 
Catheter Ablation with the Second-generation Cryoballoon 
Two large cohorts of consecutive patients with symptomatic drug-refractory paroxysmal or 
persistent AF were investigated and underwent initial CBG2-PVI from May 2012 to February 
2014. Baseline characteristics and periprocedural data were collected prospectively. Follow-up 
was performed at the institution immediately after ablation and at 1, 3, 6, 9, 12 and 18 months 
(ECG, Holter monitoring, symptoms) by referring physicians, outpatient clinics, structured 
telephone interviews and questionnaires. Data were processed using Excel 2010 (Microsoft 
Corp., Redmond, WA) and SPSS 20.0 (IBM Corp., Armonk, NY) (1, 2). 
CB procedure was performed based on an individual approach with respect to PV anatomy 
measured prior to ablation via CT or MRI scans. Two CB sizes were available. The 28-mm CB 
was used as the primary catheter if any PV diameter was >21mm. The smaller 23-mm CB was 
applied if all PV diameters were exclusively small (≤ 21mm). The insertion of a second CB size 
was allowed if PVI could not be achieved with the primary balloon. However, the use of the 23-
mm CB in larger PV (e.g. >21mm) was generally excluded (64). In this case, the CB could 
develop distal into the PV lumen which is suspected to bear a higher complication rate, e.g. PV 
stenosis or phrenic nerve palsy (64). For this reason, most centers follow a single-big balloon 
strategy for PVI. Our background of using both balloon sizes lies in our positive experience with 
the double balloon strategy with the first generation CB in persistent AF (65). Additionally, 
individual PV anatomies leave legitimate doubts whether all PV can be sufficiently isolated in all 
patients with a standardized balloon size. 
To deploy the CB in the left atrium, transseptal puncture was performed guided by fluoroscopy 
and intracardiac ultrasound (Vivid I, GE Healthcare EUROPE, GE Ultraschall Deutschland 
GmbH, Solingen, Germany). Then, the balloon was inflated and positioned at the PV ostium 
- 14 - 
 
using the Achieve™ spiral mapping catheter (8-pole) as a guide wire and for real-time PV 
potential recordings. After optimal balloon positioning was confirmed through PV angiography 
and intracardiac echocardiography (ICE), refrigerant supply was started and thus circumferential 
lesions were created in tissue-balloon contact zones leading to PVI (Figure 2, not shown in 
publications). The Achieve™ catheter was pulled back to the proximal part of the vein to record 
the PV potentials during the freeze. The time to PV isolation (TTI) was determined if feasible. At 
least two freeze-thaw-freeze cycles per vein were applied including a bonus application after 
acute PVI was achieved. PV potentials were mapped before and after each freeze cycle and at 
the end of the procedure. Additional RF touch-up applications were allowed if necessary to 
achieve electrical isolation of the vein. Phrenic nerve pacing at the right subclavian vein or the 
superior vena cava (SVC) was performed with manual palpation of the diaphragmatic motion to 
screen for phrenic nerve palsy, which is one of the main complications of CB ablation. In case of 
difficulties to feel the diaphragmatic motion, ICE was placed at the level of the right diaphragm 
and the liver to visualize the phrenic nerve function during the pacing maneuver. Furthermore, 
an endoluminal esophageal temperature probe (SensiThermTM, St. Jude Medical, Saint Paul, 
Minnesota, US) with three thermocouples was applied to detect lowest esophageal temperature 
during the applications. Standard application times per freeze were ≤ 240 and ≥ 180 seconds. 
Recent data demonstrated that 180 seconds are equally effective (66). Premature termination of 
the freeze was performed under the following circumstances: 1) phrenic nerve impairment, 2) 
low esophageal temperatures (≤+15°C), 3) low balloon temperatures when ablating the right 
sided veins (<-55°C), and 4) inefficacy of the freeze, e.g. very long TTI or high balloon 
temperatures (1, 2).  
The following part summarizes the background of the studies and the main findings. 
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Figure 2: Cryoablation procedure using the second-generation cryoballoon. Left: graphic 
viewed from the inside of the left atrium. Right: PV angiography 
 
Left: PV, pulmonary vein; CBG2, second-generation cryoballoon. Based on and modified from 
Medtronic: http://www.medtronic.com/for-healthcare-professionals/products-therapies/cardiac-
rhythm/ablation-products-for-atrial-fibrillation/arctic-front/index.htm#tab2 
Right: ET, esophageal temperature; ICE, intracardiac echocardiography; RA, right atrium, 
LSVP: left superior pulmonary vein; CB: cryoballoon and CS, coronary sinus. With kind 
permission of the Department of Cardiology and Internal Intensive Care Medicine, Municipal 
Hospital Munich-Bogenhausen 
 
 
 
 
 
 
LSVP 
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Cryoablation in Paroxysmal Atrial Fibrillation 
In publication I (page 39ff, (1)) we investigated the overall safety and efficacy of CBG2-PVI in 
patients with paroxysmal AF as well as their differences after an individualized cryoballoon 
sizing (23-mm CB, 28-mm CB, both CB) depending on PV diameter. Thereby, another main 
goal was to show whether – and under which conditions – even the 23-mm CB can be a 
reasonable ablation tool, although a higher complication rate is generally suspected. 
One hundred and ninety-seven patients with symptomatic drug-refractory paroxysmal AF 
(64±11 years, 36% female) were investigated. Cryoballoon size selection was based on pre-
procedural CT/MRI measurements (Figure 3). The 28-mm CB was the primary catheter in 47% 
(92/197 patients), the 23-mm CB in 53% (105/197, p=0.23), respectively. Significantly more 
females, patients with shorter LA diameters (each p<0.01) and smaller patients (p=0.04) were in 
the 23-mm CB group in comparison to the 28-mm CB group. Both CB sizes were necessary in 
25% (21/92 patients) after beginning the procedure with the 28-mm CB and in 23% (26/105 
patients, p=0.82) after beginning with the 23-mm CB, respectively. The main reason for a 
transition from the 28-mm CB to the 23-mm CB as a second catheter was an insufficient PV 
occlusion as a result of difficult PV anatomy. The main reason for a transition from the 23-mm 
CB to the 28-mm CB was a discordant, too large PV diameter compared to pre-procedural 
imaging results (Figure 3), which unnecessarily increased material costs. Acute PVI was 
accomplished in 99.9% of PV with cryoenergy only. Therefore, one additional focal touch-up 
ablation with RF-tip catheter was necessary to achieve PVI in one vein. Mean left atrial 
procedure time was 104±35 minutes. Mean total procedural and fluoroscopy times were 142±42 
minutes and 25±9 minutes, respectively. Further baseline characteristics and procedural data 
are shown in Table 3 and 4. The study reveals an arrhythmia- and symptom free survival of 
86% at 12 months and, at 18 months, 71% of patients were still in stable sinus rhythm 
irrespectively of the cryoballoon sizes used (Figure 4). At baseline, 41% of patients were on 
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AAD. After 12 and 18 months of follow-up, 6% of patients still received AAD treatment. There 
were no predictors for AF recurrence (Table 5). Periprocedural complication rates were low 
(4%, 8 of 197 patients; Table 6). One transient amaurosis fugax occurred as the only major 
complication (0.5%). Notably one phrenic nerve palsy (0.5%) resolved until discharge. No major 
adverse cardiac or cerebrovascular events and no PV stenosis or atrioesophageal fistula 
occurred during follow up. 
Our study shows that cryoballoon based PVI can sometimes be challenging. The 28-mm CB 
should be the primary ablation catheter in all patients. If PVI is difficult with the 28-mm CB, the 
23-mm CB is an equivalent alternative in small veins with a favorable outcome result in a safe 
procedure. Whether the 23-mm CB can be beneficial as the primary catheter in females with 
small body height and short LA diameters needs to be further investigated. 
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Figure 3: Cryoballoon utilization in patients with paroxysmal atrial fibrillation. The graphic shows our 
individualized cryoballoon size selection and the reasons for additional cryoballoon insertion 
 
PV, pulmonary vein; CB, cryoballoon; RSPV, right superior PV and PNP, phrenic nerve palsy. One focal touch-up with RF energy 
was performed in 1 PV (not shown) on the operator’s discretion (1). 
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Table 2: Baseline characteristics of patients with paroxysmal atrial fibrillation  
Data are presented as mean ± SD, median (IQR) or % of patients. Pairs of † and ‡ indicate significant 
differences.  
 
Overall 23-mm 
CB 
28-mm 
CB 
both 
CB 
P-value 
 
Number of patients 197 79 (40)
†
 71 (36)
†
 47 (24)
‡
 <0.01 
Age, years 64 ± 11 63 ± 11 65 ± 10 63 ± 11 0.65 
Female gender 71 (36) 37 (47)
†
 15 (21)
‡
 19 (40)
‡
 <0.01 
Ejection fraction, % 58 ± 4 58 ± 4 58 ± 4 57 ± 5 0.95 
LA diameter, mm 42 ± 6 40 ± 5
†
 45 ± 6
‡
 41 ± 6
†
 <0.01 
Arterial hypertension 124 (63) 51 (65) 50 (70) 23 (49) 0.09 
Hypertensive heart disease 33 (17) 10 (13) 14 (20) 9 (19) 0.61 
Structural heart disease 28 (14) 10 (13) 13 (18) 5 (11) 0.62 
     Coronary artery disease 22 (11) 8 (10) 10 (14) 4 (9) 0.79 
     Mitral Valve Insufficiency °II 1 (1) 1 (1) 0 (0) 0 (0) 0.83 
     Cardiomyopathy 5 (3) 1 (1) 3 (4) 1 (2) 0.78 
Creatinine, mg/dl 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 0.99 
Height, cm 176 ± 0.1 174 ± 0.1
†
 178 ± 0.1
‡
 176 ± 0.1 0.04 
BMI, kg/m² 26.6 ± 4 26.4 ± 5 26.7 ± 4 26.7 ± 5 0.92 
History of AF, months 
50 
(19 - 103) 
46 
(22 - 90) 
57 
(23 - 108) 
67 
(10 - 112) 
0.72 
AAD treatment at baseline 83 (42) 35 (44) 24 (34) 24 (51) 0.23 
LA, left atrium; BMI, body mass index; AF, atrial fibrillation; PVI, pulmonary vein isolation; and AAD, antiarrhythmic drug (1) 
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Table 3: Procedural data of patients with paroxysmal atrial fibrillation 
Data are presented as mean ± SD, median (IQR) or % of pulmonary veins and patients, respectively. 
Pairs of † and ‡ indicate significant differences. 
 Overall  
(n=197) 
23-mm 
CB 
28-mm 
CB 
both  
CB 
P-value 
Total procedure time, min 146 ± 42 137 ± 45
†
 141 ± 34
†
 172 ± 38
‡
 <0.01 
LA time, min 104 ± 35 97± 35
†
 97 ± 29
†
 129 ± 32
‡
 <0.01 
Fluoroscopy time, min 25 ± 9 22 ± 8
†
 25 ± 9
†
 31 ±9
‡
 <0.01 
Dose area product, cGy*cm² 
2481 
(1586 – 3810) 
2224
†
 
(1408 – 3138) 
2304
†
 
(1342 – 3783) 
2866
‡
 
(2008 – 4046) 
0.01 
Acute PVI with cryoenergy only 778/779 (99.9) 432/432 (100.0) 346/347 (99.7) – 0.91 
Focal touch-ups per vein 1/779 (0.1) 0/432 (0.0) 1/347 (0.3) – 0.91 
Ablation duration per application,s 194 ± 37 194± 41 195± 31 – 0.61 
Ablation duration per patient, s 826 ± 151 862 ± 135
†
 789 ± 167
‡
 822 ± 134 <0.01 
Applications per patient 12.1 ± 2.60 11.9 ± 2.43
†
 11.8 ± 2.57
†
 14.8 ± 2.42
‡
 <0.01 
Number of applications until PVI 1.24 ± 0.60 1.18 ± 0.49
†
 1.21 ± 0.52
†
 1.57 ± 0.97
‡
 <0.01 
Single Shot PVI, % of PV 82.7 82.9 82.4 – 0.98 
Applications per PV 2.98 ± 1.18 2.70 ± 0.96
†
 2.86 ± 1.25
†
 3.98 ± 1.17
‡
 <0.01 
Time to isolation determined 376/779 (48) 226/432 (52) 150/347 (43) – 0.01 
Time to isolation, s 39 ± 25 35 ± 24 46 ± 28 – <0.01 
LA, left atrium; PVI, pulmonary vein isolation; CB, cryoballoon; and PV, pulmonary vein (1) 
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Table 4: Intraprocedural differences and premature freezing-termination during 23-mm or 28-
mm cryoballoon application in patients with paroxysmal atrial fibrillation 
Data are presented as mean ± SD, single value or % of pulmonary veins  
Pulmonary veins (n= 779) 23-mm CB 28-mm CB P-value 
Nadir CB-temperature, °C - 56 ± 7 - 51 ± 6 <0.01 
Lowest CB-temperature, °C -78 -69  
Premature termination of the application for low 
CB-temperature 
41/434 PV (9%) 18/345 PV (5%) 0.04 
Nadir esophageal-temperature, °C +33 ± 5 +33 ± 14 0.58 
Lowest esophageal-temperature, °C +6.8 +7.1  
Premature termination of the application for low 
esophageal- temperature 
 
12/434 PV (3%) 
 
15/345 PV (4%) 0.33 
CB indicates cryoballoon, and PV, pulmonary vein (1) 
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Table 5: Univariate and multivariate analyses indicating predictors for AF recurrence after 
cryoablation for paroxysmal atrial fibrillation 
Variable β coefficient Hazard ratio 
 (95% confidence interval) 
P-value 
Univariate analysis 
Age (years) -0.016 0.98 (0.96 - 1.01) 0.22 
Female gender -0.25 0.78 (0.44 - 1.37) 0.39 
Ejection fraction (%) -0.04 0.97 (0.91 - 1.02) 0.24 
Hypertension -0.02 0.98 (0.55 - 1.73) 0.94 
LA diameter (mm) 0.01 1.01 (0.97 - 1.05) 0.71 
History of AF (months) 0.001 1.00 (1.00 - 1.00) 0.22 
Cryoballoon size    
23-mm — — 0.21 
28-mm  -0.61 0.55 (0.27 – 1.09) 0.86 
both -0.44 0.65 (0.32 – 1.30) 0.22 
Relapses in BP -0.43 1.54 (0.83 – 2.87) 0.17 
Multivariate analysis 
       Relapses in BP 0.62 1.86 (0.93 – 3.75) 0.08 
LA diameter (mm) 0.02 1.02 (0.98 - 1.07) 0.35 
Arterial hypertension 0.16 1.17 (0.63 - 2.20) 0.42 
Ejection fraction (%) -0.24 0.98 (0.92 – 1.04) 0.46 
LA, left atrium; AF, atrial fibrillation; and BP, blanking period (1) 
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Table 6: Periprocedural adverse event rates in patients with paroxysmal atrial fibrillation 
Type of complication Cryoballoon Rate (%) 
 23-mm   
(n=79) 
28-mm  
(n=71) 
both  
(n=47) 
total  
(n=197) 
 
Major adverse events  1 0.5 
Death, MI, TIA/stroke, PV stenosis    0 0.0 
Transient amaurosis fugax 1   1 0.5 
Tamponade    0 0.0 
Minor adverse events   7 3.5 
PNP recovered at discharge  1  1 0.5 
Inflammatory pericardial effusion 1 2  3 1.5 
Groin complication   1 1 0.5 
Febrile airway infection  1  1 0.5 
Urinary tract infection   1 1 0.5 
Overall adverse events  2 4 2 8 4.0 
 p=0.63  
MI, myocardial infarction; TIA, transient ischemic attack; PV, pulmonary vein, and PNP, phrenic nerve palsy (1). 
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Figure 4: Primary composite endpoint after a single procedure for patients with paroxysmal 
atrial fibrillation: Freedom from AF/AT or AF symptoms 
Kaplan–Meier estimates of freedom from AF/AT or related symptoms, with or without the use of 
antiarrhythmic drugs (A). There was no significant difference regarding the outcome of different 
balloon sizes or the usage of two balloons (B). A 3-months blanking period was considered. 
Four patients received re-ablation during the blanking period and were calculated as failure. 
Median follow-up was 13 months. 
 
 
 
AF indicates atrial fibrillation; AT, atrial tachycardia and FU, follow up (1) 
 
A  Overall 
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AF indicates atrial fibrillation; AT, atrial tachycardia and FU, follow up (1) 
 
 
 
 
 
 
 B  Depending on different cryoballoon usage 
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Cryoablation in Persistent Atrial Fibrillation 
Different ablation strategies have been proposed for the treatment of patients with persistent 
AF. At study entry, outcome data using the second generation cryoballoon for PVI in persistent 
AF patients were sparse and the method (e.g. PVI only) has been controversially discussed as 
the mechanisms to maintain persistent AF are more complex. In publication II (page 47ff, (2)), 
we investigated whether the CBG2 can be an option as a first line ablation strategy in persistent 
AF.    One hundred seventy-three patients (64±10 years, 29% female) with symptomatic drug-
refractory persistent AF were identified. Twenty-seven percent of patients presented with a 
relevant structural heart disease (coronary artery disease, cardiomyopathy or mitral valve 
insufficiency ≥ °II). One hundred fifty-seven patients (91%) completed the follow-up ≥ 12 months 
and were enrolled for the analysis of the primary endpoint. Median follow-up was 14 months 
(IQR 12-19). Acute PVI was achieved in 100% of PV. Mean left atrial time was 112 ± 30 
minutes. Mean procedure time was 155±37 minutes and the mean fluoroscopy time was 27±11 
minutes. Baseline characteristics and procedural data are shown in Table 7 and 8. At 12 
months, freedom from AF, atrial tachycardia or symptoms was achieved in 82% of patients. At 
18 months, 59% of patients were still in stable sinus rhythm (Figure 5). At baseline, 66% of 
patients were on AAD. Seventeen percent of patients at 12 months and 6% at 18 months of 
follow-up were still on AAD treatment. A relapse during the blanking period was an independent 
predictor for AF recurrence in uni- and multivariate analyses (Table 9). The complication rate 
was low (4%). Major complications occurred in 1.7% including two phrenic nerve palsies which 
resolved until discharge and one inflammatory pericardial effusion requiring pericardial drainage 
(Table 10). No major adverse cardiac or cerebrovascular events and no PV stenosis or 
atrioesophageal fistula occurred during follow up. 
The study shows, that PVI with the CBG2 is a safe and effective treatment option for patients 
with persistent AF and can be used as an initial ablation approach in persistent AF ablation. 
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Table 7: Baseline characteristics of patients with persistent atrial fibrillation 
Data are presented as mean ± SD, median (IQR) or % of patients. 
Number of patients 173 
                                                                    
157 (follow up) 
Age, years 64 ± 10 
Basal rhythm at study entry 
Sinus rhythm, n (%) 
Atrial fibrillation, n (%) 
 
     122 (78) 
       35 (22) 
Female sex 50 (29) 
Ejection fraction, % 54 ± 8 
LA diameter, mm 46 ± 7 
LA volume, ml 145 ± 39 
LA volume index, ml/m
2 
 47 ± 13 
Medical treatment at baseline, n (%) 
AAD treatment, n (%) 
Amiodarone, n (%) 
Dronedarone, n (%) 
Flecainide, n (%) 
Propafenone, n (%) 
Sotalol, n (%) 
Beta-receptor blockers, n (%) 
None, n (%) 
139 (89) 
103 (66) 
68 (43) 
17 (11) 
     11 (7) 
2 (1) 
5 (3) 
36 (23) 
18 (11) 
Arterial hypertension 123 (71) 
Hypertensive heart disease 41 (24) 
Structural heart disease 46 (27) 
Coronary artery disease 23 (13) 
Mitral Valve Insufficiency ≥ °II 12 (7) 
Cardiomyopathy 11 (6) 
Creatinine, mg/dl 0.98 ± 0.07 
BMI, kg/m² 27.3 ± 5 
History of AF, months 29 (12 - 67) 
  
Number of cardioversions 2.4 ± 1.6 
LA, left atrium; BMI, body mass index; AF, atrial fibrillation; PVI, pulmonary vein isolation; and AAD, antiarrhythmic drug (2) 
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Table 8: Procedural data of patients with persistent atrial fibrillation 
Data are presented as mean ± SD, median (IQR) or % of pulmonary veins and patients, respectively. 
                                                                 Overall (n=173 patients) 
Total procedure time, min 155 ± 37 
LA time, min 112 ± 30 
Fluoroscopy time, min 27 ± 11 
Dose area product, cGy*cm² 3230 (1870 - 5297) 
Acute PVI with CB only 673/673 (100) 
Focal touch-ups per vein 0/673 (0) 
Cryoballoon usage  
23-mm CB only 32/173 (19) 
28-mm CB only 97/173 (56) 
28-mm + 23-mm CB 44/173 (25) 
Ablation duration per PV, s 198 ± 40 
Ablation duration per patient, s 808 ± 166 
Applications per patient 12.39 ± 2.78 
Applications per PV 3.02 ± 1.19 
Number of applications until PVI 1.26 ± 0.62 
Time to isolation, s 44 ± 37 
Feasibility to determine the TTI (veins, %) 292/673 (43) 
Single Shot PVI (% of veins) 82 
LA, left atrium; PVI, pulmonary vein isolation; CB, cryoballoon; PV, pulmonary vein; and TTI, time to isolation (2) 
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Table 9: Univariate and multivariate analyses indicating predictors for AF recurrence after 
cryoablation for persistent atrial fibrillation 
Variable β coefficient Hazard ratio               
(95% confidence interval) 
P-value 
Univariate analysis 
Age (years) -0.05 0.96 (0.97 - 1.02) 0.70 
Female sex -0.23 0.80 (0.47 - 1.35) 0.40 
Ejection fraction (%) -0.32 1.00 (0.97 - 1.04) 0.84 
Hypertension -0.04 1.00 (0.59 - 1.67) 0.99 
LA diameter (mm) 0.01 1.01 (0.98 - 1.05) 0.49 
Number of cardioversions -0.28 0.76 (0.54 - 1.05) 0.10 
History of AF (months) 0.001 1.00 (1.00 - 1.01) 0.59 
Cryoballoon size    
23-mm — — 0.93 
28-mm  0.07 1.07 (0.48 - 2.40) 0.86 
28-mm + 23-mm  0.12 1.13 (0.59 - 2.16) 0.71 
Relapses in BP 0.81 2.26 (1.38 - 3.70) <0.01 
Multivariate analysis 
       Relapses in BP 0.84 2.31 (1.31 - 4.09) <0.01 
LA diameter (mm) 0.04 1.00 (0.96 - 1.05) 0.86 
Number of cardioversions -0.32 0.74 (0.51 - 1.06) 0.10 
History of AF (months) <0.01 1.00 (0.99 - 1.00) 0.70 
LA, left atrium; AF, atrial fibrillation; and BP, blanking period (2) 
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Table 10: Adverse event rates after cryoablation for persistent atrial fibrillation 
Type of Complication No. of patients 
(n=173) 
Rate, % 
Total major adverse events 3 1.73 
Death, MI, TIA/stroke  0 0.00 
PV stenosis 0 0.00 
Persistent PNP until discharge 2 1.15 
Pericardial effusion incl. drainage 1 0.57 
Total minor adverse events  4 2.31 
Groin complication 2 1.15 
Febrile airway infection 2 1.15 
Total adverse events 7 4.05 
MI, myocardial infarction; PV, pulmonary vein; TIA, transient ischemic attack; and PNP, phrenic nerve palsy (2) 
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Figure 5: Primary composite endpoint after a single procedure for patients with persistent atrial 
fibrillation: Freedom from AF/AT or AF symptoms 
The graph shows Kaplan–Meier estimates of freedom from arrhythmia with or without the use of 
antiarrhythmic medications. A 3-months blanking period was considered. Five patients were re-
ablated during the blanking period and therefore calculated as failure. Median follow-up was 14 
months. 
 
AF, atrial fibrillation; AT, atrial tachycardia and FU, follow-up (2) 
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Discussion 
The present research results validate that PVI using the CBG2 is a safe and effective treatment 
option for the index procedure of symptomatic paroxysmal (1) and also persistent AF ablation 
(2), although the method (e.g. PVI only) has been controversially discussed as the mechanisms 
in the maintenance of persistent AF are more complex. Acute PVI was achieved with the 
cryoballoon technique in 99.9% (paroxysmal AF group) and 100% (persistent AF group), 
respectively. Furthermore, the results demonstrate that PVI using the exclusive single-big 
balloon technique can be challenging in case of difficult PV anatomy, especially in small veins. 
As the single-big balloon technique is widely performed because of a suspected higher 
complication rate of the small CB, the physician needs to consider additional tools to achieve 
PVI if the big balloon fails to isolate all veins. Most physicians would switch to RF energy and 
point-by-point RF ablation to close remaining gaps after the ablation with the 28-mm CB. If 28-
mm CB PVI was difficult in the present study, the 23-mm CB was applied in small PV only (≤21-
mm) to minimize the risk of potential complications (PV stenosis, phrenic nerve palsy). 
Following this, analyses showed similar results in terms of safety and efficacy as compared to 
the big balloon. 
Freedom from atrial arrhythmia after a single cryoablation procedure was 86% at 12 months for 
patients who underwent paroxysmal AF ablation (6% on AAD), which is in range with the current 
literature on cryoablation for paroxysmal AF (67-70). Interestingly, significantly more females, 
patients with shorter LA diameters and small body height were in the 23-mm CB group. For the 
persistent AF cohort, the success rate was 82% at 12 months of follow up in our study, while 
17% of patients were still treated with antiarrhythmic drugs (59% at 18 months, 6% on AAD). 
The total adverse event rates were low in both of our study groups (4% each) with very few 
major adverse events. No death, stroke, myocardial infarction, PV stenosis or atrioesophageal 
fistula occurred during follow up. 
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Whether cryo- or radiofrequency ablation is the optimal approach in the initial ablation strategy 
has not yet been clarified. The randomized FIRE AND ICE trial (24) revealed non-inferiority of 
first and second generation cryoballoon versus RF ablation in terms of safety and efficacy for 
paroxysmal AF patients (event rate at 365 days off AAD treatment: 34.6% vs. 35.9%, p<0.001 
for non-inferiority; adverse events: 10.2% vs. 12.8%, p=0.24). Our outcome data seem to be 
superior. This can be explained by the exclusive use of the CBG2 that was technically improved 
in comparison to the first generation CB (62, 63) and might be biased by a co-treatment with 
AAD. Furthermore, our data of the persistent AF group compare well with recent findings of the 
STAR AF II trial. Here, radiofrequency PVI without additional substrate modification revealed 
freedom from arrhythmia in 59% at 18 months (60). However, Squara et al. published a 
comparative work of CBG2 and contact force RF ablation and recognized a higher rate of 
severe non-lethal complications in the RF arm (2.5% vs. none, p=0.03) (71). 
Reconnection of PV is a main predictor for AF recurrence following catheter ablation. 
Accordingly, durable PVI should come with a positive impact on clinical outcome. In our cohorts, 
81% (paroxysmal AF group) and 72% (persistent AF group) of veins of those patients who 
required second ablation procedure due to arrhythmia recurrence were still isolated (1, 2). In 
contrast, the EFFICAS I and II trial showed that the rate of durable PVI increased from 35 to 
63% of patients using contact-force guided RF ablation (72, 73), which is still substantially lower 
compared to the findings with CB. 
According to the results of our studies (1, 2) and in respect of current literature of cryo- or RF 
ablation as described above, the cryoballoon seems to be a favorable ablation tool and the 
cryoballoon technique convinces with a faster operator learning curve, a high reproducibility of 
the results across various centers and a short total procedure time (10, 23, 26, 27). 
Furthermore, insights of the FIRE AND ICE trial demonstrated significantly fewer rates of re-do 
procedures, re-hospitalizations and electrical cardioversions during follow up after cryoablation 
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in comparison to RF ablation (45). The improvement in secondary outcome measured with the 
CBG2 might lead to substantially lower healthcare system costs. Meanwhile, the novel 
guidelines on atrial fibrillation recommend RF- or cryoablation in equal measure (3, 74). 
Conclusions 
The results of the present manuscripts state that PVI using the CBG2 is a safe and highly 
effective treatment option for symptomatic paroxysmal and even persistent AF and can be 
applied in the initial ablation procedure. The 28-mm CB should be the primary ablation tool in all 
patients, but the 23-mm CB can be an alternative in small veins, if acute PVI is not achievable 
with the big balloon. Whether the 23-mm CB could play a role as the primary catheter in females 
with small body height and short LA diameter needs to be further investigated. Ongoing 
investigations for CB and RF ablation in large patient populations (FREEZE Cohort Study (75), 
NCT01360008) will give more answers to the question of the preferred technique to perform a 
safe and effective AF ablation. 
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Summary 
Pulmonary vein isolation (PVI) is the cornerstone in the catheter ablation treatment of atrial 
fibrillation (AF). Meanwhile, radiofrequency (RF) energy is the dominant energy source in use to 
perform PVI. However, the novel cryoballoon technique using cryothermal energy for PVI has 
shown promising results but outcome data are still limited and the preferred technique for the 
initial ablation has not yet been determined. The goal of this dissertation was to investigate 
baseline characteristics, procedural data, periprocedural adverse event rates and the clinical 
outcome 12 months (freedom from AF/atrial tachycardia/ AF-related symptoms) after PVI using 
the second-generation cryoballoon (CBG2) in two large groups of consecutive patients with 
symptomatic drug-refractory paroxysmal (197 patients, 64±11 years, 36% female) or persistent 
AF (173 patients, 64±10 years, 29% female). Two cryoballoon sizes were available and applied 
following an individualized anatomic approach using prior CT/MRI measurements of the PV 
diameter (all PV≤21mm: 23-mm CB as the primary catheter; one PV>21mm: 28-mm CB). If 
acute PVI was difficult with the primary balloon, the second CB size was allowed. We 
experienced that 28-mm CB PVI – most centers perform a “one size fits all” strategy – can be 
challenging because of difficult PV morphologies. In these cases, the 23-mm CB was an 
equivalent alternative to achieve PVI in small veins. Nevertheless, the 28-mm CB should be the 
primary catheter in all patients since PV diameter is not known prior to ablation in most centers. 
This might lead to a usage of the small CB in too large veins and increase the risk of 
complications (PV stenosis, phrenic nerve palsy). Furthermore, PV diameter appeared often 
larger than initially measured, which required a change to the big CB and lead to extended 
material costs. 
Acute PVI with the cryoballoon was achieved in 99.9% (paroxysmal AF) and 100% (persistent 
AF). Therefore, one additional RF focal touch-up for one PV was necessary. Total procedure 
- 36 - 
 
time was 142±42 minutes in the paroxysmal AF group and 155±37 minutes in the persistent AF 
group. At 12 months of follow-up, arrhythmia and symptom-free survival was achieved in 86% of 
patients with paroxysmal AF (6% on antiarrhythmic drugs, AAD) and in 82% of patients with 
persistent AF (17% on AAD) irrespectively of whether the 23-mm, the 28-mm or both CB sizes 
were used. A recurrence in the blanking period was the only predictor for AF recurrence (found 
in the persistent AF group). The complication rate was very low in both cohorts. 
The results state that PVI using the CBG2 is a time-saving, highly effective and safe treatment 
option for the catheter ablation of paroxysmal and even persistent AF. Until recently, PVI only 
has been controversially discussed for the ablation of persistent AF because its mechanisms 
are more complex. The actual data, however, provided an important contribution to the current 
guideline recommendations (3, 74) that meanwhile support cryoablation even in persistent AF 
as an initial ablation strategy. To the best of our knowledge, we were the first to report that 23-
mm CBG2 usage is equally safe in small pulmonary veins which can improve outcome results in 
veins that are difficult to occlude with the preferred 28-mm cryoballoon. Nevertheless, more long 
term data and comparative data of cryo- and RF-ablation are necessary to define the optimal 
initial ablation strategy. 
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Zusammenfassung 
Die Pulmonalvenenisolation (PVI) ist der Eckpfeiler der Katheterablation von Vorhofflimmern 
(VHF). Derzeit ist Radiofrequenzenergie (RF) die führende Energiequelle, welche für die PVI 
verwendet wird. Die neue Kälteballontechnologie hingegen basiert auf Kryoenergie und hat 
bislang vielversprechende Ergebnisse gezeigt. Dennoch ist die Studienlage limitiert und eine 
Empfehlung zur bevorzugten Energieform für die Erstablation von VHF konnte noch nicht 
gegeben werden. In der vorliegenden Dissertation wurde die PVI mit dem Kryoballon der 
zweiten Generation (CBG2) in zwei großen Gruppen konsekutiver Patienten mit 
symptomatischem, medikamentös-therapierefraktärem, paroxysmalen (197 Patienten, 64±11 
Jahre, 36 % weiblich) oder persistierenden VHF (173 Patienten, 64±10 Jahre, 29 % weiblich) 
durchgeführt. Das Ziel bestand darin, prozedurale Daten und Komplikationen zu erfassen sowie 
den klinischen Erfolg nach 12 Monaten (Freiheit von VHF/Atriale Tachykardie/VHF-typische 
Symptome) zu untersuchen. Zwei Cryoballongrößen waren verfügbar und wurden entsprechend 
individueller PV-Durchmesser eingesetzt. Diese wurden vorab mittels CT/MRT Untersuchungen 
vermessen. Waren alle PV-Durchmesser ≤21mm wurde der 23-mm CB als primärer 
Ablationskatheter verwendet, zeigte sich ein PV-Durchmesser >21mm, der 28-mm CB. Falls der 
Eingriff mit dem primären Ablationskatheter schwierig war, kam die zweite Ballongröße zum 
Einsatz. Wir konnten zeigen, dass die PVI mit dem 28-mm CB – die meisten Zentren verfolgen 
eine „One size fits all“ Strategie – aufgrund verschiedener PV-Morphologien eine 
Herausforderung sein kann. In diesen Fällen erwies sich der 23-mm CB als eine gleichwertige 
Alternative für kleine Venen. Nichtsdestotrotz sollte der 28-mm Ballonkatheter stets die erste 
Wahl sein, da der PV-Durchmesser in den meisten Zentren vor der Behandlung nicht bekannt 
ist. Ansonsten könnte der 23-mm CB an zu großen PV verwendet werden und ggf. 
Komplikationen wie eine PV-Stenose oder Phrenikusparese verursachen. Zusätzlich erwies sich 
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der PV-Diameter während der Prozedur häufig als größer als zuvor bestimmt, was einen 
Katheterwechsel auf den 28-mm CB notwendig machte und die Materialkosten steigern kann. 
Eine akute PVI mit der Cryoballonmethode wurde in 99.9 % (Patienten mit paroxysmalem VHF) 
und 100% (Patienten mit persistierendem VHF) erreicht. Folglich wurde eine fokale RF touch-up 
Ablation nur einer einzigen PV notwendig. Die Eingriffszeit lag in der Gruppe der paroxysmalen 
VHF Patienten bei 142±42 Minuten und in der Gruppe der Patienten mit persistierendem VHF 
bei 155±37 Minuten. Nach 12-monatigem Follow-Up konnte eine Erfolgsrate von 86 % bei 
Patieten mit paroxysmalem VHF (6 % unter antiarrhythmischer Therapie) und von 82 % bei 
Patienten mit persistierendem VHF (17 % unter antiarrhythmischer Therapie) verzeichnet 
werden. Dabei war es unerheblich, ob der Eingriff mit dem 23-mm CB, dem 28-mm CB oder 
beiden Ballons durchgeführt wurde. Der einzige statistisch signifikante Vorhersagewert für ein 
VHF-Rezidiv wurde in der persistierenden VHF Gruppe gefunden: Rezidive von Vorhofflimmern 
in der dreimonatigen Blanking Periode nach der Ablation waren ein Prädiktor für weitere 
Rezidive im Verlauf. Die Komplikationsrate war in beiden Kohorten niedrig. 
Zusammengefasst zeigen die Ergebnisse, dass die CBG2-PVI eine zeitsparende, hocheffektive 
und komplikationsarme Option in der Behandlung von paroxysmalem und persistierendem VHF 
darstellt. Bislang wurde eine alleinige PVI bei persisterendem VHF aufgrund der komplexeren 
Mechanismen kritisch gesehen. Die erhobenen Daten lieferten jedoch einen wichtigen Beitrag 
zu den aktuellen Leitlinienempfehlungen (3, 74), welche die Kryoablation nun selbst zur 
Behandlung von persistierendem VHF als Erstablation unterstützen. Anhand der uns bekannten 
Studienlage konnten wir erstmals zeigen, dass die Verwendung des 23-mm CBG2 bei kleinen 
Pulmonalvenen eine gleichwertige Alternative ist und die Erfolgsrate bei Venen, die mit dem 
favorisierten 28-mm Ballon schwierig zu okkludieren sind, steigern kann. Nichtsdestotrotz 
werden zusätzliche Langzeit- und Vergleichsdaten von Kryo- und RF-Ablation benötigt um die 
überlegene Energieform für die Erstablation von VHF zu bestimmen. 
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